Literature DB >> 10612268

Pharmacovigilance in perspective.

R H Meyboom1, A C Egberts, F W Gribnau, Y A Hekster.   

Abstract

Pharmacovigilance is more than spontaneous reporting alone, and the evaluation of marketed medicines is more than just pharmacovigilance. The positioning of a drug usually takes place during the years following introduction, when worldwide experience has accumulated. Originally a modest appendix of drug regulation, pharmacovigilance has become a major activity. The provision of the information needed for the evaluation of the benefits and risks of drugs is in the first place a scientific challenge. In addition, there are important ethical, logistical, legal, financial and commercial constraints. Good pharmacovigilance practice needs to be developed to ensure that data are collected and used in the right way and for the right purpose. Pharmacovigilance, and more generally the study of the benefits and risks of drugs, plays a major role in pharmacotherapeutic decision-making, be it individual, regional, national or international. In addition, pharmacovigilance is becoming a scientific discipline in its own right. A variety of changes are taking place in the complex system of drug development, regulation and distribution. Pharmacovigilance should be proactive in monitoring their possible consequences.

Mesh:

Year:  1999        PMID: 10612268     DOI: 10.2165/00002018-199921060-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  40 in total

1.  The UK General Practice Research Database.

Authors:  T Walley; A Mantgani
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

2.  Secret out-of-court settlements in drug-injury cases.

Authors:  A Herxheimer
Journal:  Lancet       Date:  1999-02-13       Impact factor: 79.321

3.  [From antiarrhythmic effects to pro-arrhythmic effects].

Authors:  J Caron; C Libersa; L Moreau-Guedon; D Lacroix
Journal:  Therapie       Date:  1992 Sep-Oct       Impact factor: 2.070

Review 4.  Principles of signal detection in pharmacovigilance.

Authors:  R H Meyboom; A C Egberts; I R Edwards; Y A Hekster; F H de Koning; F W Gribnau
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

Review 5.  Prescription-event monitoring--recent progress and future horizons.

Authors:  R D Mann
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

6.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

Review 7.  Good practice in the postmarketing surveillance of medicines.

Authors:  R H Meyboom
Journal:  Pharm World Sci       Date:  1997-08

8.  Voluntary systems of adverse reaction reporting--Part I.

Authors:  J P Griffin; J C Weber
Journal:  Adverse Drug React Acute Poisoning Rev       Date:  1985

9.  Introduction to neural networks.

Authors:  S S Cross; R F Harrison; R L Kennedy
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

10.  International drug monitoring: the role of national centres. Report of a WHO meeting.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1972
View more
  32 in total

Review 1.  Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?

Authors:  W K Kraft; S A Waldman
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Monitoring safety of over the counter drugs. Patients could do more than just treat themselves.

Authors:  Alan G Wade
Journal:  BMJ       Date:  2002-02-16

3.  Monitoring the safety of over the counter drugs. We need a better way than spontaneous reports.

Authors:  D Clark; D Layton; S A Shakir
Journal:  BMJ       Date:  2001-09-29

4.  Signal selection and follow-up in pharmacovigilance.

Authors:  Ronald H B Meyboom; Marie Lindquist; Antoine C G Egberts; I Ralph Edwards
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009.

Authors:  Jindrich Srba; Veronika Descikova; Jiri Vlcek
Journal:  Eur J Clin Pharmacol       Date:  2012-02-01       Impact factor: 2.953

6.  Pharmacovigilance is... Vigilance.

Authors:  I Ralph Edwards; Rachida Soulayamani Bencheikh
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

7.  Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause.

Authors:  Maria Cristina G Passarelli; Wilson Jacob-Filho; Albert Figueras
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

8.  Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; Juan Jesus Gestal-Otero
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 9.  Pharmacovigilance of biopharmaceuticals: challenges remain.

Authors:  Thijs J Giezen; Aukje K Mantel-Teeuwisse; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.